Cambridge Investment Research Advisors
KRYS icon

Cambridge Investment Research Advisors’s Krystal Biotech KRYS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Buy
+4,805
New +$1.44M ﹤0.01% 1654

Other funds holding KRYS

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Cambridge Investment Research Advisors's KRYS Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Krystal Biotech (KRYS) in Q2 2026: 4,805 shares worth $1.79M. The stake represents ﹤0.01% of the portfolio and ranks #1654 among its holdings.

103 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Cambridge Investment Research Advisors held 4,805 shares of Krystal Biotech worth $1.79M as of Q2 2026.
  • Krystal Biotech was a new Cambridge Investment Research Advisors position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1654 holding.
  • 103 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.